Top Page
Sihuan Pharmaceutical Holdings Group
(OTC:0460)
Sihuan Pharmaceutical Holdings Group (0460) vs. iShares MSCI Hong Kong ETF (EWH)
Sihuan Pharmaceutical Holdings Group Business Overview & Revenue Model
Sihuan Pharmaceutical Holdings Group Financial Statement Overview
| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 1.90B | 1.86B | 2.18B | 3.04B | 2.46B |
| Gross Profit | 1.24B | 1.30B | 1.49B | 2.43B | 1.91B |
| EBITDA | -208.66M | 334.31M | -1.54B | 931.69M | 714.06M |
| Net Income | -216.66M | -54.02M | -1.95B | 416.51M | 473.38M |
Balance Sheet | |||||
| Total Assets | 10.53B | 11.54B | 12.14B | 14.50B | 13.04B |
| Cash, Cash Equivalents and Short-Term Investments | 3.63B | 4.37B | 4.79B | 5.79B | 4.94B |
| Total Debt | 942.76M | 1.26B | 1.19B | 1.08B | 755.05M |
| Total Liabilities | 5.58B | 6.40B | 6.50B | 5.35B | 3.10B |
| Stockholders Equity | 4.37B | 4.43B | 4.74B | 8.28B | 9.19B |
Cash Flow | |||||
| Free Cash Flow | 57.51M | -95.93M | -355.97M | 64.28M | -279.51M |
| Operating Cash Flow | 243.89M | 199.49M | 46.49M | 665.29M | 227.13M |
| Investing Cash Flow | 758.24M | 169.88M | -1.66B | -337.57M | -924.78M |
| Financing Cash Flow | -1.26B | -419.56M | -238.93M | 750.66M | 184.54M |
Sihuan Pharmaceutical Holdings Group Technical Analysis
Sihuan Pharmaceutical Holdings Group Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.82B | -0.16 | -39.78% | 2.19% | 21.38% | -1.56% | |
49 Neutral | $13.90B | ― | -4.93% | 1.41% | -0.11% | -290.77% | |
| ― | $1.44B | 183.33 | 0.25% | 3.92% | ― | ― | |
| ― | €1.36B | 9.05 | 25.92% | ― | ― | ― | |
70 Outperform | HK$10.52B | 11.60 | 8.89% | 3.81% | 4.91% | -11.80% | |
65 Neutral | ― | ― | -42.02% | -76.29% | |||
49 Neutral | HK$14.93B | ― | -3.34% | ― | 45.73% | 80.77% |
Sihuan Pharmaceutical Holdings Group Corporate Events
Sihuan Pharmaceutical Holdings Group Ltd. has announced a positive profit alert, expecting to achieve a revenue of not less than RMB1,100 million and a net profit of not less than RMB50 million for the first half of 2025. This growth is driven by a significant increase in the medical aesthetics business, the successful commercialization of new innovative drugs, and a narrowing decline in the generic drug sector. The company has received approvals for 41 new products, which are anticipated to boost future revenue and profit growth.
Sihuan Pharmaceutical Holdings Group has announced the completion of the first patient enrollment in a Phase III clinical trial for Anaprazole Sodium Enteric Coated Tablets, targeting reflux esophagitis. This development marks an expansion of indications for the drug, which is the first and only fully independently developed proton pump inhibitor (PPI) in China. The trial, involving multiple leading medical institutions, aims to evaluate the drug’s efficacy and safety, potentially broadening its market reach and creating commercial synergies. The growing prevalence of reflux esophagitis and peptic ulcers in China, combined with the drug’s unique properties, positions it for significant clinical and commercial success.
Sihuan Pharmaceutical Holdings Group Ltd. announced a voluntary share purchase under its 2022 Share Award Scheme, acquiring 10,000,000 shares, which represents approximately 0.11% of the total shares issued. This move is part of the company’s strategic efforts to enhance its market position and incentivize its stakeholders, reflecting its commitment to growth and leadership in the pharmaceutical and medical aesthetic industries.
Sihuan Pharmaceutical Holdings Group Ltd. has announced a share repurchase plan of up to HK$500 million, with a recent repurchase of 20 million shares at an average price of HK$1.0910 per share. This move is part of the company’s strategy to enhance shareholder value and reflects confidence in its growth prospects. The company has made significant strides in its medical aesthetics and innovative pharmaceuticals sectors, with substantial revenue growth and the launch of numerous new products. This expansion is expected to drive future revenue and profit growth, reinforcing Sihuan Pharmaceutical’s position in the industry.
Sihuan Pharmaceutical Holdings Group announced that their New Drug Application for a new indication of Bireociclib Tablets, in combination with aromatase inhibitors for first-line treatment of HR+/HER2- advanced breast cancer, has been accepted by China’s National Medical Products Administration. This development highlights the company’s strong R&D capabilities and positions them to provide comprehensive treatment options for breast cancer patients, addressing a significant demand in the global market for CDK4/6 inhibitors, which is projected to grow substantially.
Sihuan Pharmaceutical Holdings Group Ltd. held its Annual General Meeting on June 6, 2025, where all proposed resolutions were passed by shareholder vote. Key resolutions included the re-election of directors, re-appointment of Ernst & Young as auditors, and authorization for the board to manage share issuance and repurchase. These decisions reflect the company’s stable governance structure and strategic focus on maintaining financial and operational flexibility, potentially impacting its market positioning positively.
Sihuan Pharmaceutical Holdings Group Ltd. announced that its subsidiary, Xuanzhu Biopharmaceutical Co., Ltd., has received marketing authorization from the National Medical Products Administration for its innovative drug, Bireociclib Tablets, for two indications in HR+/HER2- advanced breast cancer. This approval marks a significant milestone as Bireociclib is the only CDK4/6 inhibitor approved in China for monotherapy in later-line treatment, showcasing the company’s strong R&D capabilities. The drug’s approval is expected to address treatment bottlenecks in breast cancer therapy, offering a promising solution for patients with limited options.
Sihuan Pharmaceutical Holdings Group announced a share repurchase plan of up to HK$500 million, with the recent repurchase of 10 million shares at an average price of HK$0.6888 per share. This move is part of the company’s strategy to enhance shareholder value and reflects its confidence in future growth. Sihuan has made significant progress in its medical aesthetics and pharmaceuticals segments, with substantial revenue growth and new product approvals. The company anticipates these developments will positively impact its revenue and profit, reinforcing its position in the industry.
Sihuan Pharmaceutical Holdings Group announced a share repurchase plan, buying back 20 million shares at an average price of HK$0.7342 per share, reflecting a strategic move to enhance shareholder value. The company has shown significant progress in its medical aesthetics and innovative pharmaceuticals sectors, with a notable revenue increase in its medical aesthetics business and the approval of 28 new products, which are expected to positively impact future revenue and profit.